Literature DB >> 6086749

Binding to and antibacterial effect of ampicillin, neomycin and polymyxin B on human faeces.

M P Hazenberg, A M Pennock-Schröder, M Van den Boom, J P Van de Merwe.   

Abstract

Neomycin and polymyxin B, used during selective decontamination of the gastrointestinal tract, were studied for their effect on the human faecal flora in vitro. The selective effect was found to be associated with a relative insusceptibility of the obligate anaerobic flora as compared with the facultatively anaerobic Gram-negative rods (Escherichia coli). Both neomycin and polymyxin B were bound by human faeces, in contrast to ampicillin. The results may explain the selective effect of neomycin and polymyxin B on the human flora in vivo.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6086749      PMCID: PMC2129264          DOI: 10.1017/s0022172400060897

Source DB:  PubMed          Journal:  J Hyg (Lond)        ISSN: 0022-1724


  16 in total

1.  TREATMENT OF SALMONELLA CARRIERS WITH COLISTIN SULFATE.

Authors:  S P GOTOFF; M H LEPPER; M A FIEDLER
Journal:  Am J Med Sci       Date:  1965-04       Impact factor: 2.378

2.  Oral dose and faecal concentration of antibiotics during antibiotic decontamination in mice and in a patient.

Authors:  D van der Waaij; J M Berghuis-de Vries; C Korthals Altes
Journal:  J Hyg (Lond)       Date:  1974-10

3.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

4.  Antimicrobial prophylaxis against infection in neutropenic patients.

Authors:  L S Young
Journal:  J Infect Dis       Date:  1983-04       Impact factor: 5.226

5.  Effects of the human intestinal flora on germ-free mice.

Authors:  M P Hazenberg; M Bakker; A Verschoor-Burggraaf
Journal:  J Appl Bacteriol       Date:  1981-02

6.  The microbial contribution to human faecal mass.

Authors:  A M Stephen; J H Cummings
Journal:  J Med Microbiol       Date:  1980-02       Impact factor: 2.472

7.  Selective antimicrobial modulation of human microbial flora: infection prevention in patients with decreased host defense mechanisms by selective elimination of potentially pathogenic bacteria.

Authors:  H F Guiot; J W van der Meer; R van Furth
Journal:  J Infect Dis       Date:  1981-05       Impact factor: 5.226

8.  The faecal flora of patients with Crohn's disease.

Authors:  F Wensinck; P A Poppelaars-Kustermans; A M Schröder
Journal:  J Hyg (Lond)       Date:  1981-08

9.  Susceptibility of anaerobic bacteria to ten antimicrobial agents.

Authors:  P C Appelbaum; S A Chatterton
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

10.  Bacteriological aspects of selective decontamination of the digestive tract as a method of infection prevention in granulocytopenic patients.

Authors:  H G de Vries-Hospers; D T Sleijfer; N H Mulder; D van der Waaij; H O Neiweg; H K van Saene
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

View more
  5 in total

1.  Enterobacteriaceae suppression by three different oral doses of polymyxin E in human volunteers.

Authors:  J J van Saene; H K van Saene; N J Tarko-Smit; G J Beukeveld
Journal:  Epidemiol Infect       Date:  1988-06       Impact factor: 2.451

Review 2.  Colonization resistance.

Authors:  E J Vollaard; H A Clasener
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

3.  Binding to and antibacterial effect of aztreonam, temocillin, gentamicin and tobramycin on human faeces.

Authors:  M P Hazenberg; A M Pennock-Schröder; J P van de Merwe
Journal:  J Hyg (Lond)       Date:  1985-10

4.  Selective decontamination and the anaerobic faecal flora.

Authors:  M P Hazenberg; A M Pennock-Schröder
Journal:  Antonie Van Leeuwenhoek       Date:  1984       Impact factor: 2.271

Review 5.  Selective Intestinal Decontamination as a Method for Preventing Infectious Complications (Review).

Authors:  A L Barsuk; E S Nekaeva; L V Lovtsova; A L Urakov
Journal:  Sovrem Tekhnologii Med       Date:  2020-12-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.